**Supplemental Digital Content 1: chemotherapy regimens**

|  |  |  |  |
| --- | --- | --- | --- |
| **Abbrevation** | **Agents included**  | **Total** **N= 419** | **%** |
| **TAC**  | Docetaxel, doxorubin, cyclophoshamide  | 139 | 32.9 |
| **FEC or AC**  | 5-fluorocacil, epirubicin, cyclophosphamide (FEC), doxorubicin and cyclophosphamide (AC)  | 60 | 14.3 |
| **FEC + doce.** | 5-fluorocacil, epirubicin, cyclophosphamide, docetaxel  | 98 | 23.3 |
| **AC/EC followed by taxanes (sequential regime)** | Doxorubicin, cyclophosphamide, paclitaxel  | 110 | 26.3 |
| **Miscellaneous**  | Docetaxel, capecitabine, paclitaxel, epirubicin, cyclophosphamide  | 12 | 2.9 |

Description of regimens classified as ‘miscellaneous’:

* Combination therapy docetaxel and capecitabine (n=5)
* Combination therapy of capecitabine and paclitaxel (n=3)
* Monotherapy paclitaxel (n=3)
* Epirubicin, cyclophosphamide and docetaxel, all given sequential (n=1)